These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 1675053)

  • 1. Alpha 1 blockers: antihypertensives whose positive metabolic profile with regard to hyperinsulinaemia and lipid metabolism cannot be ignored.
    Waite MA
    J Intern Med Suppl; 1991; 735():113-7. PubMed ID: 1675053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations.
    Pool JL; Lenz ML; Taylor AA
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():23-33. PubMed ID: 1979819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic changes during antihypertensive therapies.
    Krone W; Nägele H
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():69-73; discussion 74. PubMed ID: 2575177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
    Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
    Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive drugs and the hypertensive diabetic patient.
    Feher M
    J Hum Hypertens; 1990 Oct; 4 Suppl 3():7-9. PubMed ID: 1979821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum lipoproteins during treatment with antihypertensive drugs.
    Weidmann P; de Courten M; Ferrari P; Böhlen L
    J Cardiovasc Pharmacol; 1993; 22 Suppl 6():S98-105. PubMed ID: 7508069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of alpha inhibitors on risk cofactors in patients with hypertension].
    Plouin P
    Ann Cardiol Angeiol (Paris); 1989 Dec; 38(9 Pt 2):577-9; discussion 580. PubMed ID: 2576348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Terazosin: a new antihypertensive agent with favorable effects on lipids.
    Luther RR
    Int J Clin Pharmacol Ther Toxicol; 1989 Jul; 27(7):313-9. PubMed ID: 2570758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpha blockers: a reassessment of their role in therapy.
    Cauffield JS; Gums JG; Curry RW
    Am Fam Physician; 1996 Jul; 54(1):263-6, 269-70. PubMed ID: 8677841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The treatment of hypertension in patients with a metabolic disorder].
    Dal Palù C; Semplicini A
    Ann Ital Med Int; 1995 Oct; 10 Suppl():130S-132S. PubMed ID: 8562259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive agents and cardiovascular risk factors.
    Fodor JG
    Clin Ther; 1986; 8(5):490-509. PubMed ID: 2876774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
    Pool JL
    Br J Clin Pract Suppl; 1994 May; 74():8-12. PubMed ID: 8049119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes.
    Glanz M; Garber AJ; Mancia G; Levenstein M
    Int J Clin Pract; 2001 Dec; 55(10):694-701. PubMed ID: 11777296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha 1-blockade for the treatment of hypertension: a megastudy of terazosin in 2214 clinical practice settings.
    Itskovitz HD
    Clin Ther; 1994; 16(3):490-504. PubMed ID: 7923316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-blocker therapy; a possible advance in the treatment of diabetic hypertension--results of a cross-over study of doxazosin and atenolol monotherapy in hypertensive non-insulin dependent diabetic subjects.
    Feher MD; Henderson AD; Wadsworth J; Poulter C; Gelding S; Richmond W; Sever PS; Elkeles RS
    J Hum Hypertens; 1990 Oct; 4(5):571-7. PubMed ID: 1980930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between antihypertensive agents, serum lipids and cigarette smoking in high risk hypertensive patients.
    Plouin PF
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():49-53; discussion 53-4. PubMed ID: 2575176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Alpha-adrenoceptor antagonist (blocker)].
    Shigetomi S
    Nihon Rinsho; 1997 Aug; 55(8):2055-60. PubMed ID: 9284423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.